Bahl & Gaynor’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$613M Sell
666,129
-121,251
-15% -$123M 3.09% 4
2025
Q4
$846M Sell
787,380
-16,600
-2% -$15.9M 4.28% 3
2025
Q3
$613M Sell
803,980
-27,509
-3% -$20.5M 3.05% 6
2025
Q2
$648M Sell
831,489
-12,911
-2% -$10M 3.28% 5
2025
Q1
$697M Sell
844,400
-7,490
-0.9% -$6.23M 3.55% 3
2024
Q4
$658M Sell
851,890
-11,708
-1% -$9.69M 3.48% 4
2024
Q3
$765M Sell
863,598
-1,759
-0.2% -$1.58M 3.94% 2
2024
Q2
$783M Sell
865,357
-12,442
-1% -$9.95M 4.38% 2
2024
Q1
$683M Sell
877,799
-18,770
-2% -$13.4M 3.8% 2
2023
Q4
$523M Sell
896,569
-38,504
-4% -$22.5M 3.14% 4
2023
Q3
$502M Sell
935,073
-28,074
-3% -$14.5M 3.21% 4
2023
Q2
$452M Sell
963,147
-145,114
-13% -$60.9M 2.75% 8
2023
Q1
$381M Buy
1,108,261
+129,726
+13% +$43.8M 2.05% 15
2022
Q4
$358M Sell
978,535
-68,625
-7% -$24.3M 2.24% 14
2022
Q3
$339M Buy
1,047,160
+63,459
+6% +$20.1M 2.24% 14
2022
Q2
$319M Buy
983,701
+115,686
+13% +$34.7M 2.1% 15
2022
Q1
$249M Sell
868,015
-319,727
-27% -$82.3M 1.83% 18
2021
Q4
$328M Sell
1,187,742
-27,422
-2% -$6.95M 1.83% 19
2021
Q3
$281M Buy
1,215,164
+24,293
+2% +$6M 1.72% 20
2021
Q2
$273M Buy
1,190,871
+34,340
+3% +$6.9M 1.66% 22
2021
Q1
$216M Buy
1,156,531
+5,057
+0.4% +$989K 1.37% 31
2020
Q4
$194M Buy
1,151,474
+52,169
+5% +$7.79M 1.24% 32
2020
Q3
$163M Sell
1,099,305
-9,893
-0.9% -$1.53M 1.15% 36
2020
Q2
$182M Buy
1,109,198
+31,258
+3% +$4.8M 1.37% 32
2020
Q1
$150M Buy
1,077,940
+71,522
+7% +$9.83M 1.3% 32
2019
Q4
$132M Buy
1,006,418
+269,860
+37% +$31.3M 0.92% 38
2019
Q3
$82.4M Sell
736,558
-148,185
-17% -$16.5M 0.6% 47
2019
Q2
$98M Buy
884,743
+214,787
+32% +$25.3M 0.73% 43
2019
Q1
$86.9M Buy
669,956
+71,644
+12% +$8.71M 0.8% 38
2018
Q4
$69.2M Buy
598,312
+406,912
+213% +$45.5M 0.74% 40
2018
Q3
$20.5M Buy
191,400
+163,091
+576% +$16.3M 0.26% 71
2018
Q2
$2.42M Buy
28,309
+192
+0.7% +$15.8K 0.03% 197
2018
Q1
$2.17M Sell
28,117
-1,156
-4% -$93.1K 0.02% 206
2017
Q4
$2.47M Buy
29,273
+356
+1% +$30.3K 0.03% 188
2017
Q3
$2.47M Sell
28,917
-250
-0.9% -$20.5K 0.03% 178
2017
Q2
$2.4M Sell
29,167
-169
-0.6% -$13.8K 0.03% 171
2017
Q1
$2.47M Buy
29,336
+169
+0.6% +$13.5K 0.03% 168
2016
Q4
$2.15M Sell
29,167
-11
-0% -$819 0.03% 170
2016
Q3
$2.34M Sell
29,178
-46
-0.2% -$3.68K 0.03% 162
2016
Q2
$2.3M Buy
29,224
+116
+0.4% +$8.73K 0.03% 160
2016
Q1
$2.1M Buy
29,108
+369
+1% +$27.9K 0.03% 163
2015
Q4
$2.42M Buy
28,739
+1,526
+6% +$127K 0.03% 152
2015
Q3
$2.28M Buy
27,213
+674
+3% +$56.9K 0.03% 161
2015
Q2
$2.22M Sell
26,539
-108
-0.4% -$8.23K 0.03% 165
2015
Q1
$1.94M Buy
26,647
+1,080
+4% +$76.9K 0.03% 181
2014
Q4
$1.76M Buy
25,567
+1,107
+5% +$74.7K 0.02% 182
2014
Q3
$1.59M Sell
24,460
-30,000
-55% -$1.9M 0.02% 186
2014
Q2
$3.39M Sell
54,460
-138
-0.3% -$8.23K 0.05% 134
2014
Q1
$3.21M Sell
54,598
-924
-2% -$51.6K 0.05% 136
2013
Q4
$2.83M Sell
55,522
-3,762
-6% -$188K 0.05% 144
2013
Q3
$2.98M Buy
59,284
+29
+0% +$1.52K 0.05% 133
2013
Q2
$2.91M Buy
+59,255
New +$3.22M 0.06% 131

Other funds holding LLY

Bahl & Gaynor's LLY Position: Q1 2026 in Review

Bahl & Gaynor reduced its Eli Lilly (LLY) stake by 15% in Q1 2026, selling an estimated $123M and leaving 666,129 shares worth $613M. The position accounts for 3.09% of the portfolio, ranked #4.

Bahl & Gaynor first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $846M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bahl & Gaynor held 666,129 shares of Eli Lilly worth $613M as of Q1 2026.
  • Bahl & Gaynor sold 121,251 Eli Lilly shares in Q1 2026, an estimated $123M.
  • Eli Lilly made up 3.09% of Bahl & Gaynor's portfolio in Q1 2026, its #4 holding.
  • Bahl & Gaynor first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Bahl & Gaynor's Eli Lilly position peaked at $846M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.